Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study
Background & Aims To evaluate the hypothesis that increasing T cell frequency and activity
may provide durable control of hepatitis B virus (HBV), we administered nivolumab, a
programmed death receptor 1 (PD-1) inhibitor, with or without GS-4774, an HBV therapeutic
vaccine, in virally suppressed patients with HBV e antigen (HBeAg)-negative chronic HBV.
Methods In a phase Ib study, patients received either a single dose of nivolumab at 0.1
mg/kg (n= 2) or 0.3 mg/kg (n= 12), or 40 yeast units of GS-4774 at baseline and week 4 and …
may provide durable control of hepatitis B virus (HBV), we administered nivolumab, a
programmed death receptor 1 (PD-1) inhibitor, with or without GS-4774, an HBV therapeutic
vaccine, in virally suppressed patients with HBV e antigen (HBeAg)-negative chronic HBV.
Methods In a phase Ib study, patients received either a single dose of nivolumab at 0.1
mg/kg (n= 2) or 0.3 mg/kg (n= 12), or 40 yeast units of GS-4774 at baseline and week 4 and …
